Cytoprotection in head and neck cancer

Issues in oral care

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Efforts to enhance the therapeutic index in the treatment of head and neck cancer by improving efficacy and limiting toxicity involve both physical and cytoprotective approaches. Although intensity-modulated radiation therapy is moderately effective for reducing damage to the parotid glands and protecting the part of salivary activity produced by those glands, it has not proven effective for protecting the submandibular glands, which are responsible for the saliva that provides oral comfort. Cytoprotective agents, such as amifostine, and salivary gland stimulants, such as pilocarpine, are used to prevent or compensate for some of the xerostomia that follows radiotherapy or combined chemoradiotherapy for cancers of the head and neck.

Original languageEnglish
Pages (from-to)9-12
Number of pages4
JournalJournal of Supportive Oncology
Volume2
Issue number6 SUPPL. 3
StatePublished - Nov 1 2004

Fingerprint

Cytoprotection
Head and Neck Neoplasms
Radiotherapy
Amifostine
Xerostomia
Pilocarpine
Submandibular Gland
Parotid Gland
Chemoradiotherapy
Salivary Glands
Saliva
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cytoprotection in head and neck cancer : Issues in oral care. / Samuels, Michael A.

In: Journal of Supportive Oncology, Vol. 2, No. 6 SUPPL. 3, 01.11.2004, p. 9-12.

Research output: Contribution to journalArticle

@article{032e406b0bb34e319fa5712fbacc690d,
title = "Cytoprotection in head and neck cancer: Issues in oral care",
abstract = "Efforts to enhance the therapeutic index in the treatment of head and neck cancer by improving efficacy and limiting toxicity involve both physical and cytoprotective approaches. Although intensity-modulated radiation therapy is moderately effective for reducing damage to the parotid glands and protecting the part of salivary activity produced by those glands, it has not proven effective for protecting the submandibular glands, which are responsible for the saliva that provides oral comfort. Cytoprotective agents, such as amifostine, and salivary gland stimulants, such as pilocarpine, are used to prevent or compensate for some of the xerostomia that follows radiotherapy or combined chemoradiotherapy for cancers of the head and neck.",
author = "Samuels, {Michael A}",
year = "2004",
month = "11",
day = "1",
language = "English",
volume = "2",
pages = "9--12",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "6 SUPPL. 3",

}

TY - JOUR

T1 - Cytoprotection in head and neck cancer

T2 - Issues in oral care

AU - Samuels, Michael A

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Efforts to enhance the therapeutic index in the treatment of head and neck cancer by improving efficacy and limiting toxicity involve both physical and cytoprotective approaches. Although intensity-modulated radiation therapy is moderately effective for reducing damage to the parotid glands and protecting the part of salivary activity produced by those glands, it has not proven effective for protecting the submandibular glands, which are responsible for the saliva that provides oral comfort. Cytoprotective agents, such as amifostine, and salivary gland stimulants, such as pilocarpine, are used to prevent or compensate for some of the xerostomia that follows radiotherapy or combined chemoradiotherapy for cancers of the head and neck.

AB - Efforts to enhance the therapeutic index in the treatment of head and neck cancer by improving efficacy and limiting toxicity involve both physical and cytoprotective approaches. Although intensity-modulated radiation therapy is moderately effective for reducing damage to the parotid glands and protecting the part of salivary activity produced by those glands, it has not proven effective for protecting the submandibular glands, which are responsible for the saliva that provides oral comfort. Cytoprotective agents, such as amifostine, and salivary gland stimulants, such as pilocarpine, are used to prevent or compensate for some of the xerostomia that follows radiotherapy or combined chemoradiotherapy for cancers of the head and neck.

UR - http://www.scopus.com/inward/record.url?scp=11944255565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11944255565&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 9

EP - 12

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 6 SUPPL. 3

ER -